Filtered By:
Specialty: Urology & Nephrology
Condition: Heart Failure
This page shows you your search results in order of date.
Order by Relevance | Date
Total 162 results found since Jan 2013.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis
CONCLUSION: Finerenone produces similar cardiorenal benefits in Asian and non-Asian patients.PMID:37708857 | DOI:10.1159/000532102
Source: American Journal of Nephrology - September 14, 2023 Category: Urology & Nephrology Authors: Daisuke Koya Stefan D Anker Luis M Ruilope Peter Rossing ZhiHong Liu Byung Wan Lee Chien-Te Lee Charlie Scott Peter Kolkhof Robert Lawatscheck Lili Wang Amer Joseph Bertram Pitt FIDELIO-DKD Investigators Source Type: research
Association of intradialytic hypertension with future cardiovascular events and mortality in hemodialysis patients: effects of ambulatory blood pressure
CONCLUSIONS: IDHTN patients had higher risk for mortality and cardiovascular outcomes but this risk is at least partly confounded by the elevated BP levels during the interdialytic period.PMID:37302385 | DOI:10.1159/000531477
Source: American Journal of Nephrology - June 11, 2023 Category: Urology & Nephrology Authors: Fotini Iatridi Marieta P Theodorakopoulou Antonios Karpetas Vasiliki Sgouropoulou Areti Georgiou Eleni Karkamani Artemios Karagiannidis Aikaterini Papagianni Pantelis A Sarafidis Source Type: research
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients With Chronic Kidney Disease and Renal Anemia
Am J Nephrol. 2023 May 16. doi: 10.1159/000531084. Online ahead of print.ABSTRACTRenal anemia is treated with erythropoiesis-stimulating agents (ESA), even though epoietin alfa and darbepoietin increase the risk of cardiovascular death and thromboembolic events, including stroke. Hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD) inhibitors have been developed as an alternative to ESAs, producing comparable increases in hemoglobin. However, in advanced chronic kidney disease, HIF-PHD inhibitors can increase the risk of cardiovascular death, heart failure and thrombotic events to a greater extent than that with ES...
Source: American Journal of Nephrology - May 26, 2023 Category: Urology & Nephrology Authors: Milton Packer Source Type: research
The number of valvular insufficiency is a strong predictor of cardiovascular and all-cause mortality in hemodialysis patients
ConclusionsIn maintenance HD patients, the prevalence of VI is prominently high. The number of VI ≥ 2 is associated with emergency hospitalized for acute heart failure, cardiovascular and all-cause mortality. Combining age, number of VI ≥ 2, and albumin can predict cardiovascular and all-cause mortality.
Source: International Urology and Nephrology - April 3, 2023 Category: Urology & Nephrology Source Type: research
Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes
CONCLUSION: Quality of life was impaired in patients starting haemodialysis. A higher C-reactive protein level level was a consistent independent predictor of the majority of worse quality of life. Transferrin saturation ≤ 20% was associated with worse physical component score of quality of life. Baseline quality of life was predictive of all-cause mortality and the primary outcome measure.EUDRACT REGISTRATION NUMBER: 2013-002267-25.PMID:36995528 | PMC:PMC10061401 | DOI:10.1007/s40620-023-01571-6
Source: Journal of Nephrology - March 30, 2023 Category: Urology & Nephrology Authors: Sunil Bhandari Patrick Parfrey Claire White Stefan D Anker Kenneth Farrington Ian Ford Philip A Kalra John J V McMurray Michele Robertson Charles R V Tomson David C Wheeler Iain C Macdougall PIVOTAL Investigators, Committees Source Type: research
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis
Conclusions The cardiovascular benefits and safety profile of finerenone in participants with stage 4 CKD were consistent with the overall FIDELITY population; this was also the case for albuminuria and the rate of eGFR decline. The effects on the composite kidney outcome were not consistent over time.PMID:36927680 | DOI:10.2215/CJN.0000000000000149
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 17, 2023 Category: Urology & Nephrology Authors: Pantelis Sarafidis Rajiv Agarwal Bertram Pitt Christoph Wanner Gerasimos Filippatos John Boletis Katherine R Tuttle Luis M Ruilope Peter Rossing Robert Toto Stefan D Anker Zhi-Hong Liu Amer Joseph Christiane Ahlers Meike Brinker Robert Lawatscheck George Source Type: research
